SingleTimeMicroneedles
Delivering drugs and vaccines to the world

Jasdeep Singh, Ed.D., MBAjasdeep.singh@stmpatch.com
860-847-0138
stmpatch.com

The Problem: Deployment
Labor:

Labor can more than 200%
the cost of the dose

Supply Chain:

Cold chain can be up to
2x the cost of the dose

Injections are a driving cost

Cold chain is limiting

Compliance:
Multiple dosings are problematic

25% of owners reportforgetting doses

The Result

Current Model Costs Lives, Money, Health
To Thousands of Farmers$1.8M Losses from a single porcine disease PER DAY (USA)To Billions of People

50% Reduction in dairy herd yield
To Millions of Patients

Increased Parasitic infections (25%)

The Solution
Unique Advantage: Multi-Dose and Temp-StablePatches
●●●●✓
✓
✓

Painless patch is removed
Invisible needles are embedded with vaccines & drugs
Multi-dose, longitudinal dose, or single dose
Patented technology (1 issued (US, EU, India, China), 4 in various stages)

No missed doses
No cold chain
Lowered deployment costs

The Preclinical Evidence:
Effective and Easier
Improved Vaccine Effectiveness0 fatalities(more protective)

Reliable Drug Bioavailability

1 painless patch versus
4 painful injections

The Supply Chain
Savings Throughout The Steps
●
●
●
●

●
●Greater eﬃcacy
Equal/higherbioavailability
No missed doses
No Pain●No biohazard/sharps waste
Target species
applicator

●

●

●

Up to 42% cheaper
manufacturing
Reducedcarrying-inventory
costs

300% decrease inshipping density
No cold storageat any stepThe Team:
Depth and Breadth

Jasdeep Singh, MBA

Thanh Nguyen, Ph.D.

Nicholas Farrell, MS

Steven Szczepanek, Ph. D.

Co-Founder & CEO

Research Lead, Engineering

Co-Founder & CTO

Market Expert, Vaccinology/Immunology

The Board

Responsibility to Balance Risks and Rewards

Jasdeep Singh, MBAThanh Nguyen, Ph.D.

Co-Founder & CEO

Co-Founder & CTO

Linh Le

Serial Entrepreneur

Richard Mazzola

Project MedTech, Secretary

Dylan Bermes

Heath Advance Partners, Investor

The Traction:

Market-Based Development
Revenue & Partnerships
Animal Vaccine Market$11.8B Market, 9.3% CAGR
Paid+
Proﬁt

Veterinary Vaccine Development with Top
10 Human/Vet Pharma Company

Science-Market Leadership
Finalist: MedicalThreat Reduction
June 2024

mRNA-LNP Pilot Study (Vet-Human)Space and Funding in Late-Stage Negotiation
for International Expansion

Closed $500k Pre-Seed Round | Revenue Positive Q1 2024

The Revenue Model:
Diversiﬁed
TODAY

UPCOMING
Contract ResearchOrganization
Pharma partnership drug
and patch development

Contract Manufacturing
Organization
Manufacture R&D andpre-clinical patches

Royalties & Licensing
Sales on co-developedproducts

B2B Sales
Develop STM brandedproducts

The Pathway

One market opens to another
Human
Biologics

AnimalBiologics

AnimalSmall
Molecule

Master File
Human

Human
Small
Molecule

SERIES B
SERIES A

SEEDYear 3

Year 4

SecondPotential ExitFirst
Potential Exit
Year 5

Year 6

Year 7Year 8Year 9

The regulatory pathway from animal to human offers a continuous revenue-generating
pathway with multiple high-return potential exits for investors

The Pathway:
One Healthier WorldTOTAL ANIMAL MARKET(Drugs and Vaccines)$40B
6.8% CAGR

OpenTHE HUMAN MARKET

$50B

$81B

$75B

27% CAGR

Diabetes/Obesity

Vaccines

Pain

The Call to Action

Improve community health multiple doses at a time
TWO WAYS TO HELP

Seed Round (For Accredited
Investors Only)● Accelerate drug
stabilization andmanufacturing research● Complete internal
target-species pilot studies● Submit data to USDA/EU

Develop with us

Jasdeep Singh, Ed.D., MBA | jasdeep.singh@stmpatch.com
860-847-0138 | stmpatch.com